Pharmaceutical Drug Delivery Market Report 2026-2031, By Administration Route, Application, and Geo

Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031

USD USD 2,922.82 BN

MARKET SIZE, 2031

CAGR 6.3%

(2026-2031)

1500

REPORT PAGES

1700

MARKET TABLES

PHARMACEUTICAL DRUG DELIVERY MARKET SIZE, SHARE & GROWTH SNAPSHOT

drug-delivery-technologies-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global pharmaceutical drug delivery market is projected to grow from USD 2,152.45 billion in 2026 to USD 2,922.82 billion by 2031, at a CAGR of 6.3% during the forecast period. The market was valued at USD 2,077.13 billion in 2025. The rise in demand for advanced drug delivery systems due to the rapid growth of biologics and biosimilars worldwide is driving the market, leading to investments in more drug dosage forms and large-volume injectable technologies. Besides, the increasing number of chronic diseases such as cancer, diabetes, and autoimmune disorders worldwide is also urging the demand for self administration and patient centric delivery solutions. The transition to home-based and wearable drug delivery systems is helping patients stick to their treatments and at the same time, increasing the usage of smart, connected, and sensor, enabled injectors. The high research activity in top drug delivery and pharmaceutical sciences journals also indicates a strong interest in innovative drug delivery technologies. Continuing improvements in prefilled syringes, transdermal delivery, and connected devices, as well as higher investments in pharmaceutical research, still act as a source of market growth.

KEY TAKEAWAYS

By Route of Administration

By route of administration, the injectable drug delivery segment dominated the market with 40.3% market share in 2025.
By Application

By application, the injectable drug delivery application segment is expected to register the highest CAGR of 7.9% between 2026 and 2031.
By Facility of Use

By facility of use, the formulations segment is expected to dominate the market, with a share of 59.3% in 2025.
Competitive Landscape - Key Players

Johnson & Johnson Services (US), Pfizer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), BD (US), Novartis AG (Switzerland), were identified as the star players in the pharmaceutical drug delivery market, given their extensive global reach and comprehensive product portfolios.
Competitive Landscape - Startups

AdhexPharma (France), and Rusan Pharma (India) have distinguished themselves among startups and SMEs due to their innovations in drug delivery systems, novel delivery technologies, and specialized formulation capabilities focused on improving patient convenience and therapeutic outcomes.

The global pharmaceutical drug delivery market is witnessing a steady growth, which can be attributed to the increasing demand for complex biologics that necessitate advanced injectable, transdermal, inhalation, and large-volume drug delivery systems. The trend of self administration as patients with chronic diseases manage their conditions at home is also a key factor behind this rise. Besides, rapid progress in wearable injectors, smart prefilled syringes, and smart drug delivery systems that enhance adherence and enable real-time monitoring is paving the way for further growth. Pharmaceutical companies are dedicating a considerable portion of their budget to new drug formulations that include long acting injectables, nanoparticle based delivery, controlled release dosage forms, and novel drug delivery systems to increase drug efficacy and patient comfort. At the same time, regulatory measures aimed at minimizing medication errors and ensuring the safety of device drug combinations are still the main factors encouraging the use of advanced drug delivery technologies that are easy to use in healthcare facilities.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The massive trends and transformations, as well as the shift from traditional small molecule therapies to biologics, have begun to trigger a paradigm shift in the global pharmaceutical drug delivery market. This paradigm shift is characterized by heavy investments in next-generation injectable platforms, wearable drug delivery systems, and biologic-compatible technologies in various geographies. This paradigm change is also being accompanied by the rapid proliferation of connected and sensor, equipped devices that enable digital therapy management, electronic health system integration, and remote patient monitoring, as well as the growing worldwide trend for self-administration to reduce clinic and hospital visits. Besides that, groundbreaking medical devices such as on-body injectors, microneedle patches, nanoparticle based carriers, and smart inhalers are transforming drug delivery by providing more precise dosage, better patient adherence, and greater convenience for patients. Nevertheless, global supply-chain challenges, sterility requirements, and stricter regulatory expectations for drug–device combination products are compelling pharmaceutical manufacturers to adopt more automated, user-centric, and technology-integrated delivery platforms.

drug-delivery-technologies-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Rising global demand for biologics, biosimilars, and complex therapies
Increasing shift toward self-administration and home-based care worldwide

RESTRAINTS

Impact
Level

High development costs and stringent global regulatory requirements
Infections associated with needlestick injuries

OPPORTUNITIES

Impact
Level

Geographic expansion into emerging markets
Integration with digital health & remote monitoring

CHALLENGES

Impact
Level

Pricing pressure by governing bodies
Limited patient training and adherence issues for advanced self-administration and wearable delivery systems

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing shift toward self-administration and home-based care worldwide

At present, patients as well as the healthcare sector are moving toward home care for the treatment of chronic diseases due to the convenience and cost-effectiveness. This has resulted in an increased demand for self-administered drug delivery systems such as auto-injectors, on-body injectors, and wearable injectors. These devices help patients in following a regular regimen and are a part of the drug delivery system.

Restraint: High development costs and stringent global regulatory requirements

The development of advanced drug delivery systems involves complex R&D, the use of specialized materials, large-scale sterile manufacturing, and quality control, all of which contribute to a substantial increase in the cost of production of biologics, next-generation injectables, and combination products. These high costs are further exacerbated by stringent and varied global regulatory requirements in the US, Europe, and Asia, where formulations and device-drug combinations are required to adhere to stringent requirements for safety, efficacy, and performance.

Opportunity: Increasing adoption of long-acting and targeted delivery technologies

Globally, there has been a rise in the use of long-acting injectables, nanoparticle formulations, microneedle patches, and targeted drug delivery systems. Such technologies help improve drug bioavailability, reduce the number of times drugs have to be taken, and increase treatment specificity, especially in the cases of cancer, neurology, and immunology. More and more investment in precision medicine and advanced formulations is helping to create big opportunities for companies which are engaged in the development of next generation drug delivery technologies.

Challenge: Complex regulatory environments, supply chain, and sterility issues

The global pharmaceutical drug delivery industry is challenged by complex regulatory environments, long approval cycles, and high quality standards for device-drug combination products. The regulatory environment poses a challenge to the development of new drug delivery systems. On the other hand, the industry is also challenged by high sterility standards, cold chain logistics, and a delicate global supply chain that is, at times, threatened by component shortages and supply chain disruptions.

PHARMACEUTICAL DRUG DELIVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Offers advanced delivery platforms such as osmotic oral systems, transdermal patches, implantable pumps, liposomal systems, and controlled-release technologies across major therapeutic areas	Controlled and targeted release for improved adherence \| Broad expertise across oral, transdermal, implantable, and injectable formats \| Support for biologics and long-acting therapies
	Provides oral solids, injectables, sustained-release, liposomal, and nanoparticle-based delivery systems; invests in delivery for mRNA and complex biologics	Support for consistent and flexible delivery of small molecules and biologics \| Strong R&D and global manufacturing \| Rapid commercialization of new delivery technologies
	Specializes in implantable, port-based, and sustained-release platforms; strong presence in injectable delivery for oncology, immunology, and ophthalmology	Enhanced localized/sustained administration \| Reduced dosing frequency \| Improved compliance \| Expertise in biologics and ADCs \| Support for high-value targeted therapies
	Provides prefillable syringes, safety systems, autoinjectors, pen injectors, and BD Libertas wearable injector supporting combination product development and self-administration	Low development risk \| Accelerated market entry \| Strong manufacturing \| Safety features \| Improved adherence and support home-based delivery
	Develops drug–device and advanced delivery systems including inhalation platforms, injectable biologics, and subcutaneous technologies; expanding infrastructure for radioligand and cell-based therapies	Improved adherence and outcomes \| Expertise in complex therapies \| Precision dosing \| Regulatory readiness \| Global supply reliability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The pharmaceutical drug delivery market is driven by major pharmaceutical companies, niche device manufacturers, CDMOs, healthcare institutions, and government authorities across different geographies. The market is witnessing a transformation to cater to the increasing demand for safer, more convenient, and patient-friendly drug delivery systems. Heavy investments in biologics, nanotechnology, and controlled release are driving the innovations in injectables, inhalation devices, transdermal systems, and self-administration devices. Government authorities, such as the US FDA, EMA, PMDA, and the China, and Indian regulatory authorities are facilitating this transition by improving the regulations for combination products and quality. On the contrary, the increasing incidence of chronic diseases, aging population, and the trend toward home-based care are driving the demand for wearable injectors, long-acting formulations, and digital drug delivery devices, thus transforming the global drug delivery market.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Pharmaceutical Drug Delivery Market, By Route of Administration

The injectable drug delivery segment held the largest market share in the global pharmaceutical drug delivery market in 2025. A considerable part of the market growth will be contributed from biologics, monoclonal antibodies, vaccines, and other large, molecule therapies that need parenteral administration. Moreover, the escalating global burden of chronic diseases, including cancer, diabetes, autoimmune disorders, and cardiovascular diseases, is boosting the demand for reliable, precise, and efficient dosing solutions, wherein injectables have an added advantage over oral routes. Worldwide, patients and healthcare providers prefer self, administration tools, e.g., autoinjectors, prefilled syringes, pen injectors, and wearable injectors, which facilitate convenience and fewer clinical visits. Importance of safety engineered devices, needle-free injectors, and on-body delivery platforms in this segment can be seen in that these technologies improve adherence, usability, and treatment experience in various healthcare environments.

Pharmaceutical Drug Delivery Market, By Application

In the pharmaceutical drug delivery market, by application, injectable drug delivery is expected to be the fastest-growing segment during the forecast period. This segment is driven by the rising prevalence of chronic and complex diseases such as cancer, autoimmune disorders, and metabolic conditions, which increasingly rely on injectable therapies for effective treatment. Injectables enable accurate dosing, faster therapeutic action, and higher bioavailability, making them essential for biologics, vaccines, and advanced therapies including gene and cell treatments. The strong expansion of oncology, immunology, and infectious disease treatments largely dependent on parenteral administration is further accelerating demand across these application areas. Additionally, advancements in drug delivery technologies, such as prefilled syringes, autoinjectors, and long-acting injectables, are improving patient compliance and supporting the shift toward self-administration and home care.

Pharmaceutical Drug Delivery Market, By Facility of Use

In the pharmaceutical drug delivery marker, the formulations segment—comprising hospitals, ambulatory surgical centers/clinics, home care settings, diagnostic centers, and long-term care facilities—accounted for the largest market share in 2025 and is expected to maintain its dominance during the forecast period. This is because these settings represent the final point of care where drug products are administered to patients, directly driving consumption volumes across all routes of administration. Hospitals hold the largest share within this segment due to their advanced infrastructure, availability of skilled healthcare professionals, and ability to handle complex therapies, such as injectables, biologics, oncology treatments, and critical care medications. The growing burden of chronic diseases, increasing surgical procedures, and rising hospital admissions further strengthen demand in this setting.

REGION

Asia Pacific to be fastest-growing region in global pharmaceutical drug delivery market during forecast period

The Asia Pacific pharmaceutical drug delivery market is expected to witness the fastest growth rate during the forecast period supported by the increasing healthcare expenditure, the setting up of pharmaceutical manufacturing plants, and the growing application of advanced therapies in China, India, Japan, and South Korea. Additionally, the need for advanced drug delivery systems, especially for biologics, biosimilars, and specialty medicines, is driven by the rapid urbanization, the growing middle class population, and the broader insurance coverage. More spending on hospitals, specialty clinics, and integrated care centers is leading to an increase in the use of injectable, inhalation, transdermal, and self, administrated delivery devices such as autoinjectors and wearable injectors. The excellent biosimilar production capabilities and the growth of local R&D contribute significantly to the support of cost, efficient delivery technology adoption in the region.

drug-delivery-technologies-market Region

PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX

In the pharmaceutical drug delivery formulations market matrix, the star players are Johnson & Johnson, Pfizer, Roche, and Novartis. These players are highly benefited from their R&D capabilities, various delivery modes, and leadership in biologics, oncology, vaccines, and chronic disease therapies. Their position of dominance is supported by especially trustworthy technologies such as sustained release technologies, implantable devices, smart injectors, lipid nanoparticle technologies, and drug combinations. These players are also benefited from large-scale manufacturing, regulatory knowledge, and tech support. On the other hand, the emerging leaders in the industry are Boehringer Ingelheim International GmbH. These players are making rapid progress by concentrating on particular delivery modes. These delivery modes include microneedles, wearables, nanoparticle technologies, implants for ocular delivery, and innovations for biologic delivery through subcutaneous. In addition to the large-scale suppliers, niche technology suppliers and medium-scale players are also expanding their knowledge in inhalation technologies, skin patches, depot injections, and digital delivery devices. The convergence of resources and capabilities of established players and the innovative and technology-driven strengths of new entrants is changing the pharmaceutical drug delivery market into a highly competitive and rapidly expanding market. Similarly, in pharmaceutical drug delivery device market, the star players are BD and Stevanato Group and the emerging leaders in this market are SHL Medical and others.

drug-delivery-technologies-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

Johnson & Johnson (US)
Novartis AG (Switzerland)
F. Hoffmann-La Roche (Switzerland)
Pfizer Inc. (US)
Eli Lilly and Company (US)
GSK plc (UK)
AbbVie Inc. (US)
Merck & Co. (US)
Bausch Health Companies Inc.(Canada)
Bayer AG (Germany)
Amgen, Inc. (US)
Boehringer Ingelheim International GmbH (Germany)
AstraZeneca (UK)
Company Name (Devices)
BD (US)
Cardinal Health (US)
B.Braun SE (Germany)
Terumo Corporation (Japan)
Nipro (Japan)
Stevanato Group (Italy)
Gerresheimer AG (Germany)
West Pharmaceutical Services (US)
Ypsomed (Switzerland)
SHL Medical (Switzerland)

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2025 (Value)	USD 2,077.13 Billion
Market Forecast in 2031 (Value)	USD 2,922.82 Billion
Growth Rate	CAGR of 6.3% from 2026–2031
Years Considered	2024–2031
Base Year	2025
Forecast Period	2026–2031
Units Considered	Value (USD Million/Billion), Volume (Ten Thousand Units)
Report Coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered	By Route of Administration: Oral Drug Delivery Injectable Drug Delivery Topical Drug Delivery Ocular Drug Delivery Pulmonary Drug Delivery Nasal Drug Delivery Implantable Drug Delivery Transmucosal Drug Delivery Otic Drug Delivery By Application: IOral Drug Delivery Injectable Drug Delivery Topical Drug Delivery Ocular Drug Delivery Pulmonary Drug Delivery Nasal Drug Delivery Implantable Drug Delivery Transmucosal Drug Delivery Otic Drug Delivery By Facility of Use: Devices Formulations
Regions Covered	North America, Europe, Asia Pacific, Latin America, the Middle East & Africa

WHAT IS IN IT FOR YOU: PHARMACEUTICAL DRUG DELIVERY MARKET REPORT CONTENT GUIDE

drug-delivery-technologies-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Product Analysis	Global market comparison of major drug delivery methods, such as oral solid dosage forms (OSD), injectables (prefilled syringes, autoinjectors, depot injections), inhalation devices, transdermal patches, implants, and liposomal or nanoparticle carriers, as well as wearable/connected drug delivery devices. Controlled-release mechanisms, bioavailability enhancement, targeted delivery, pain-free administration systems, and biologics compatibility were compared across regions. Regulatory expectations from global agencies (FDA, EMA, PMDA, NMPA, CDSCO), innovation trends, formulation challenges, and differentiation strategies used by leading multinational manufacturers were evaluated.	Enabled clients to identify which drug delivery technologies are most beneficial across global therapeutic segments considering efficacy, patient convenience, and adherence. Highlighted region-specific maturity to guide adoption of long-acting injectables, combination products, or nano-based platforms. Helped clients benchmark innovation levels (e.g., mRNA delivery, smart injectors) across regions and align product development with global needs in chronic disease management, biologics administration, and home-based self-treatment.
Company Information	Created profiles of major global companies and regional players active in drug delivery, including Johnson & Johnson, Pfizer, Roche, Novartis, Merck, BD, West Pharmaceutical Services, Catalent, AbbVie, AstraZeneca, Amgen, Sanofi, and others. Assessed company portfolios in advanced injection systems, inhalation technologies, controlled-release formulations, nanoparticle systems, digital/connected devices, and combination-product development. Evaluated strengths such as biologic delivery capabilities, sustained-release technologies, autoinjector platforms, manufacturing capacity, and global regulatory readiness.	Included comparative positioning, technological strengths, and partnership ecosystems across global pharma and drug-device integrators. Supported supplier evaluation for prefilled syringes, autoinjectors, biologic-ready containers, and advanced delivery technologies. Guided clients in selecting partners for licensing, co-development, outsourcing, or biologics delivery innovation. Expanded understanding of long-term company strategies, competitive differentiation, and regional leadership across high-growth therapeutic segments worldwide.
Geographic Analysis	Provided comprehensive analysis of global trends in pharmaceutical drug delivery across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Assessed regional regulatory frameworks (FDA, EMA, PMDA, NMPA, CDSCO), biologics adoption, patient-oriented delivery preferences, and development of local manufacturing ecosystems. Evaluated reimbursement structures, home-care growth, digital health integration, and high-potential hubs in Europe (Germany, Switzerland), APAC (China, India, Japan, South Korea), and LATAM. Offered region-level customization including adoption rates, investment hotspots, partnerships, and technology maturity.	Supported strategic decision-making by pinpointing high-growth global delivery modalities (injectables, autoinjectors, wearable pumps, nanoparticle systems). Assisted in evaluating localization opportunities, supply-chain expansion, and optimal regions for manufacturing or partnerships. Enabled clients to identify global patient-preference trends, driven by biologics, aging populations, and rising home-care delivery. Country-level analysis strengthened clients’ ability to expand in diverse international markets with tailored entry and growth strategies.

RECENT DEVELOPMENTS

May 2026 : Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved ICOTYDE (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.
March 2026 : Novartis announced that it has entered an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.
December 2025 : US Food and Drug Administration (FDA) approved F. Hoffmann-La Roche's CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

105

EXECUTIVE SUMMARY

111

PREMIUM INSIGHTS

116

MARKET OVERVIEW

Innovative drug delivery tech and biologics drive growth amid regulatory and pricing challenges.

120

4.1

INTRODUCTION

4.2

MARKET DYNAMICS

4.2.1

DRIVERS

4.2.1.1

ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES

4.2.1.2

RISING BURDEN OF CHRONIC DISEASES AND AGING POPULATION

4.2.1.3

GROWING ADOPTION OF BIOLOGICS AND BIOSIMILARS

4.2.1.4

GROWING EMPHASIS ON PATIENT CONVENIENCE

4.2.1.5

INCREASING INVESTMENTS IN PHARMACEUTICAL R&D

4.2.2

RESTRAINTS

4.2.2.1

INFECTIONS ASSOCIATED WITH NEEDLESTICK INJURIES

4.2.2.2

STRINGENT GOVERNMENT REGULATIONS

4.2.3

OPPORTUNITIES

4.2.3.1

GEOGRAPHIC EXPANSION INTO EMERGING MARKETS

4.2.3.2

INTEGRATION WITH DIGITAL HEALTH & REMOTE MONITORING

4.2.4

CHALLENGES

4.2.4.1

PRICING PRESSURE BY GOVERNING BODIES

4.3

UNMET NEEDS & WHITE SPACES

4.3.1

UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET

4.3.2

WHITE SPACE OPPORTUNITIES

4.4

INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.4.1

INTERCONNECTED MARKETS

4.4.2

CROSS-SECTOR OPPORTUNITIES

4.5

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

4.5.1

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

INDUSTRY TRENDS

Navigate competitive forces and pricing dynamics to capitalize on emerging pharmaceutical delivery trends.

135

5.1

PORTER’S FIVE FORCES ANALYSIS

5.1.1

THREAT OF NEW ENTRANTS

5.1.2

THREAT OF SUBSTITUTES

5.1.3

BARGAINING POWER OF SUPPLIERS

5.1.4

BARGAINING POWER OF BUYERS

5.1.5

INTENSITY OF COMPETITIVE RIVALRY

5.2

MACROECONOMIC INDICATORS

5.2.1

INTRODUCTION

5.2.2

GDP TRENDS & FORECAST

5.2.3

TRENDS IN GLOBAL HEALTHCARE INDUSTRY

5.2.4

TRENDS IN GLOBAL PHARMACEUTICAL DRUG DELIVERY INDUSTRY

5.3

VALUE CHAIN ANALYSIS

5.4

ECOSYSTEM ANALYSIS

5.5

PRICING ANALYSIS

5.5.1

AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025

5.5.1.1

AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023−2025

5.5.1.2

AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023−2025

5.5.1.3

AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023−2025

5.5.2

AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023–2025

5.5.2.1

AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.5.2.2

AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.5.2.3

AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.5.2.4

AVERAGE SELLING PRICE TREND OF PULMONARY DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.5.2.5

AVERAGE SELLING PRICE TREND OF OCULAR DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.5.2.6

AVERAGE SELLING PRICE TREND OF NASAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025

5.6

TRADE ANALYSIS

5.6.1

TRADE DATA FOR HS CODE 3004

5.6.1.1

IMPORT DATA FOR HS CODE 3004

5.6.1.2

EXPORT DATA FOR HS CODE 3004

5.6.2

TRADE DATA FOR HS CODE 9018

5.6.2.1

IMPORT DATA FOR HS CODE 9018

5.6.2.2

EXPORT DATA FOR HS CODE 9018

5.7

KEY CONFERENCES & EVENTS, 2026–2027

5.8

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.9

INVESTMENT & FUNDING SCENARIO

5.10

REIMBURSEMENT ANALYSIS

5.11

PIPELINE ANALYSIS

5.12

SUCCESS STORIES & REAL-WORLD APPLICATIONS

5.12.1

MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM

5.12.2

YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY

5.12.3

ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE

5.13

IMPACT OF US TARIFFS—PHARMACEUTICAL DRUG DELIVERY MARKET

5.13.1

INTRODUCTION

5.13.2

KEY TARIFF RATES

5.13.3

PRICE IMPACT ANALYSIS

5.13.4

IMPACT ON COUNTRIES/REGIONS

5.13.5

IMPACT ON END-USE INDUSTRIES

5.13.5.1

IMPACT ON END-USE INDUSTRIES: FORMULATIONS

5.13.5.1.1

HOSPITALS

5.13.5.1.2

AMBULATORY SURGICAL CENTERS/CLINICS

5.13.5.1.3

HOME CARE SETTINGS

5.13.5.2

IMPACT ON END-USE INDUSTRIES: DEVICES

5.13.5.2.1

PHARMACEUTICAL COMPANIES

5.13.5.2.2

BIOTECHNOLOGY COMPANIES

5.13.5.2.3

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) & CONTRACT RESEARCH ORGANIZATIONS (CROS)

TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

AI is revolutionizing drug delivery with personalized, minimally invasive, and smart monitoring technologies.

175

6.1

TECHNOLOGY ANALYSIS

6.1.1

KEY EMERGING TECHNOLOGIES

6.1.1.1

NANOTECHNOLOGY-BASED DRUG DELIVERY

6.1.1.2

SMART/CONNECTED DRUG DELIVERY DEVICES

6.1.1.3

NEEDLE-FREE INJECTION SYSTEMS AND MICRONEEDLE PATCHES

6.1.2

COMPLEMENTARY TECHNOLOGIES

6.1.2.1

3D PRINTED & PERSONALIZED DRUG DELIVERY

6.1.2.2

AI/ML IN DRUG DELIVERY & FORMULATION

6.1.3

ADJACENT TECHNOLOGIES

6.1.3.1

SMART MONITORING, IOT, AND DATA-DRIVEN CONTROL

6.1.3.2

CELL & GENE DELIVERY VECTORS

6.2

TECHNOLOGY/PRODUCT ROADMAP

6.2.1

NEAR-TERM (2025–2027)

6.2.2

MID-TERM (2028–2030)

6.2.3

LONG-TERM (2030+)

6.3

PATENT ANALYSIS

6.3.1

PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY MARKET

6.3.2

JURISDICTION & TOP APPLICANT ANALYSIS

6.4

FUTURE APPLICATIONS

6.4.1

PATIENT-CENTRIC DRUG DELIVERY SYSTEMS

6.4.2

MINIMALLY INVASIVE AND SELF-ADMINISTERED DELIVERY

6.4.3

LONG-ACTING AND BIOLOGIC DRUG DELIVERY SYSTEMS

6.4.4

DIGITAL AND AI-ENABLED DRUG DELIVERY

6.5

IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRUG DELIVERY MARKET

6.5.1

INTRODUCTION

6.5.2

MARKET POTENTIAL IN PHARMACEUTICAL DRUG DELIVERY ECOSYSTEM

6.5.3

AI USE CASES

6.5.4

KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET

SUSTAINABILITY & REGULATORY LANDSCAPE

Navigate complex global regulations to drive sustainable practices in pharmaceutical manufacturing.

187

7.1

REGIONAL REGULATIONS & COMPLIANCE

7.1.1

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.1.2

INDUSTRY STANDARDS

7.2

SUSTAINABILITY INITIATIVES

7.2.1

ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN PHARMACEUTICAL DRUG DELIVERY

7.3

SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

7.4

CERTIFICATIONS, LABELING, AND ECO-STANDARDS

CUSTOMER LANDSCAPE & BUYER BEHAVIOR

Unlock strategic insights into buyer dynamics and unmet needs shaping market profitability.

197

8.1

BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA

8.1.1

KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES)

8.1.2

KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS)

8.1.3

BUYING CRITERIA

8.2

CUSTOMER LANDSCAPE & BUYER BEHAVIOR

8.2.1

DECISION-MAKING PROCESS

8.2.2

ADOPTION BARRIERS & INTERNAL CHALLENGES

8.2.3

UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

8.2.4

MARKET PROFITABILITY

PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION

Market Size & Growth Rate Forecast Analysis to 2031 in USD Billion and Units | 170 Data Tables

203

9.1

INTRODUCTION

9.2

INJECTABLE DRUG DELIVERY

9.2.1

DEVICES

9.2.1.1

CONVENTIONAL INJECTION DEVICES

9.2.1.1.1

RISING INCIDENCE OF CHRONIC DISEASES AND LOW COST OF MANUFACTURING TO DRIVE THE MARKET

9.2.1.1.2

GLOBAL VOLUME ANALYSIS OF CONVENTIONAL INJECTION DEVICES, 2024-2031(TEN THOUSAND UNITS)

9.2.1.1.3

BY MATERIAL

9.2.1.1.4

BY USABILITY

9.2.1.1.5

BY TYPE

9.2.1.1.6

PREFILLED SYRINGES

9.2.1.2

SELF-INJECTION DEVICES

9.2.1.2.1

GLOBAL VOLUME ANALYSIS OF SELF-INJECTION DEVICES, 2024-2031(TEN THOUSAND UNITS)

9.2.1.2.2

NEEDLE-FREE INJECTORS

9.2.1.2.3

AUTOINJECTORS

9.2.1.2.4

PEN INJECTORS

9.2.1.2.5

WEARABLE INJECTORS

9.2.1.3

OTHER INJECTABLE DEVICES

9.3

FORMULATIONS

9.3.1

BY TYPE

9.3.1.1

CONVENTIONAL DRUG DELIVERY FORMULATIONS

9.3.1.2

NOVEL DRUG DELIVERY FORMULATIONS

9.3.1.3

LONG-ACTING INJECTABLE FORMULATIONS

9.3.2

BY FORMULATION PACKAGING

9.3.2.1

AMPOULES

9.3.2.1.1

HELPS MAINTAIN THE STABILITY OF DRUGS, THEREBY ENHANCING EFFICACY

9.3.2.2

VIALS

9.3.2.2.1

ABILITY TO STORE DRUG FORMULATIONS FOR EXTENSIVE PERIODS

9.3.2.3

CARTRIDGES

9.3.2.3.1

OFFERS HIGHER DOSE ACCURACY AND PATIENT CONVENIENCE

9.3.2.4

BOTTLES

9.3.2.4.1

EASY STORAGE OF SOLUTIONS AND EMULSIONS DRIVES DEMAND

9.4

ORAL DRUG DELIVERY

9.4.1

SOLID ORAL DRUGS

9.4.1.1

TABLETS

9.4.1.1.1

DEVELOPMENT OF MINI-TABLETS IS A KEY TREND IN THIS MARKET SEGMENT

9.4.1.2

CAPSULES

9.4.1.2.1

EASY ABSORPTION OF DRUGS AND DECREASED IRRITATION IN GI TRACT DRIVE USE OF CAPSULES

9.4.1.3

POWDERS

9.4.1.3.1

POWDERS ARE TAKEN BY PATIENTS WHO ARE UNABLE TO SWALLOW ORAL DOSAGE FORMS

9.4.1.4

GRANULES

9.4.1.4.1

INCREASING ADOPTION OF MODIFIED-RELEASE AND PEDIATRIC-FRIENDLY FORMULATIONS DRIVING GRANULES MARKET GROWTH

9.4.1.5

LOZENGES

9.4.1.5.1

PROLONGED DRUG RELEASE AND LOCALIZED ACTION ENHANCING ADOPTION OF LOZENGES

9.4.2

LIQUID ORAL DRUGS

9.4.2.1

SYRUPS

9.4.2.1.1

EASY ADMINISTRATION TO PATIENTS WITH SWALLOWING DIFFICULTIES

9.4.2.2

SOLUTIONS

9.4.2.2.1

GERIATRIC AND PEDIATRIC PATIENTS GENERALLY PREFER SOLUTIONS

9.4.2.3

EMULSIONS

9.4.2.3.1

EMULSIONS OFFER ENHANCED SOLUBILITY AND STABILITY WITH EASE OF ADMINISTRATION

9.4.2.4

SUSPENSIONS

9.4.2.4.1

INCREASING DEMAND FOR PEDIATRIC AND GERIATRIC-FRIENDLY FORMULATIONS IS DRIVING THE ORAL SUSPENSION MARKET GROWTH

9.4.2.5

ELIXIRS

9.4.2.5.1

ELIXIRS ARE A PREFERRED CHOICE FOR THE PEDIATRIC POPULATION

9.4.3

SEMI-SOLID ORAL DRUGS

9.4.3.1

GELS

9.4.3.1.1

GELS ARE USED FOR CONTROLLED DRUG RELEASE

9.4.3.2

PASTES

9.4.3.2.1

MICROEMULSIONS OFFER PROTECTION AGAINST OXIDATION AND ENZYMATIC HYDROLYSIS

9.5

TOPICAL DRUG DELIVERY

9.5.1

SEMI-SOLID FORMULATIONS

9.5.1.1

OINTMENTS

9.5.1.1.1

OINTMENTS ARE WIDELY USED IN ANALGESIC INDICATIONS

9.5.1.2

CREAMS

9.5.1.2.1

CREAMS ARE EITHER WATER-IN-OIL OR OIL-IN-WATER EMULSIONS

9.5.1.3

LOTIONS

9.5.1.3.1

EASY ADMINISTRATION OF LOTIONS TO DRIVE DEMAND AMONG END USERS

9.5.1.4

GELS

9.5.1.4.1

FASTER DRUG RELEASE AND GREATER PATIENT ACCEPTABILITY TO DRIVE THE MARKET FOR TOPICAL GELS

9.5.1.5

PASTES

9.5.1.5.1

TOPICAL PASTES ARE WIDELY USED FOR THE TREATMENT AND PREVENTION OF SKIN IRRITATION

9.5.2

LIQUID FORMULATIONS

9.5.2.1

SUSPENSIONS

9.5.2.1.1

HIGHER RATE OF BIOAVAILABILITY AND CONTROLLED ONSET OF ACTION TO DRIVE MARKET

9.5.2.2

EMULSIONS

9.5.2.2.1

IMPROVED SPREADABILITY, STABILITY, AND CONTROLLED RELEASE OF ACTIVE INGREDIENTS

9.5.2.3

SOLUTIONS

9.5.2.3.1

UNIFORM & RAPID DRUG DELIVERY TO BOOST DEMAND

9.5.3

SOLID FORMULATIONS

9.5.3.1

POWDERS

9.5.3.1.1

POWDERS HAVE A VERY FINE PARTICLE SIZE THAT COVERS A LARGE SURFACE AREA PER UNIT WEIGHT

9.5.3.2

SUPPOSITORIES

9.5.3.2.1

SUPPOSITORIES REQUIRE A SUITABLE BASE TO ENSURE THE COMPATIBILITY AND STABILITY OF THE DRUG

9.5.4

FILMS

9.5.4.1

NEXT-GENERATION ADVANCEMENTS TO BOOST DEMAND

9.5.5

TRANSDERMAL FORMULATIONS

9.5.5.1

TRANSDERMAL PATCHES

9.5.5.1.1

TRANSDERMAL PATCHES PREVENT PREMATURE METABOLIZATION OF DRUGS THROUGH THE LIVER

9.5.6

TRANSDERMAL GELS

9.5.6.1

RAPID RELEASE OF DRUGS TO FUEL UPTAKE

9.5.7

TRANSDERMAL SPRAYS

9.5.7.1

TARGETED APPROACH TO BOOST DEMAND

9.6

OCULAR DRUG DELIVERY

9.6.1

LIQUID FORMULATIONS

9.6.1.1

EYE DROPS

9.6.1.1.1

RISING PREVALENCE OF CATARACTS AND OTHER EYE DISEASES TO DRIVE THE MARKET GROWTH

9.6.1.2

LIQUID SPRAYS

9.6.1.2.1

LIQUID SPRAYS TO HELP IN OVERCOMING DRAWBACKS ASSOCIATED WITH TRADITIONAL EYE DROPS

9.6.2

SEMI-SOLID FORMULATIONS

9.6.2.1

GELS

9.6.2.1.1

HIGH VISCOSITY OF DRUGS, PROLONGED DRUG RELEASE, AND EASE OF DRUG ADMINISTRATION CONTRIBUTE TO MARKET GROWTH

9.6.2.2

EYE OINTMENTS

9.6.2.2.1

EYE OINTMENTS ARE SAFE TO USE AND HELP IN IMPROVING OCULAR CONTACT TIME WITH THE DRUG

9.6.3

OCULAR DEVICES

9.6.3.1

DRUG-COATED CONTACT LENSES

9.6.3.1.1

BETTER EYESIGHT OFFERED BY LENSES AND HIGH COMPLIANCE TO DRIVE THE MARKET FOR DRUG-COATED CONTACT LENSES

9.6.3.2

OCULAR INSERTS

9.6.3.2.1

OCULAR INSERTS TO HELP IN THE SUSTAINED RELEASE OF DRUGS IN THE EYE

9.7

PULMONARY DRUG DELIVERY

9.7.1

PULMONARY DRUG DELIVERY DEVICE

9.7.1.1

METERED-DOSE INHALERS

9.7.1.2

METERED-DOSE INHALERS OVERCOME THE PROBLEM OF POOR COORDINATION BETWEEN INHALER ACTUATION AND PATIENT BREATH

9.7.1.2.1

GLOBAL VOLUME ANALYSIS OF METERED DOSE INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)

9.7.1.3

DRY POWDER INHALERS

9.7.1.3.1

DRY POWDER INHALER FORMULATIONS ARE CHEMICALLY MORE STABLE THAN THEIR COUNTERPARTS

9.7.1.3.2

GLOBAL VOLUME ANALYSIS OF DRY POWDER INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)

9.7.1.4

NEBULIZERS

9.7.1.4.1

GLOBAL VOLUME ANALYSIS OF NEBULIZERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS)

9.7.1.4.2

JET NEBULIZERS

9.7.1.4.3

ULTRASONIC NEBULIZERS

9.7.1.4.4

SOFT MIST NEBULIZERS

9.7.2

PULMONARY DRUG DELIVERY FORMULATION

9.7.2.1

SUSPENSION AEROSOL

9.7.2.2

SUSPENSION AEROSOLS ENABLE DELIVERY OF INSOLUBLE DRUG FORMULATIONS

9.7.2.3

SOLUTION AEROSOL

9.7.2.3.1

SOLUTION AEROSOLS SUPPORT UNIFORM DRUG DISTRIBUTION AND FORMULATION FLEXIBILITY

9.7.3

DRY POWDER FORMULATIONS

9.8

NASAL DRUG DELIVERY

9.8.1

NASAL DROPS & LIQUIDS

9.8.1.1

NASAL DROPS ARE CONSIDERED MORE EFFICIENT THAN NASAL SPRAYS

9.8.2

NASAL SPRAYS

9.8.2.1

NASAL SPRAYS TO HELP IN RELIEVING NASAL CONGESTION, RUNNY NOSE, ITCHY NOSE, AND SNEEZING

9.8.3

NASAL POWDERS

9.8.3.1

ABSENCE OF PRESERVATIVES AND SUPERIOR STABILITY OF FORMULATIONS ARE SOME ADVANTAGES ASSOCIATED WITH NASAL POWDERS

9.9

TRANSMUCOSAL DRUG DELIVERY

9.9.1

ORAL FORMULATIONS

9.9.1.1

BUCCAL DRUG DELIVERY

9.9.1.1.1

BUCCAL DRUG DELIVERY SYSTEM IS SUITABLE FOR LOCAL AND SYSTEMIC THERAPIES

9.9.1.2

SUBLINGUAL DRUG DELIVERY

9.9.1.2.1

HIGHER RATE OF DRUG ABSORPTION COMPARED TO ORAL ROUTE DRIVES ADOPTION

9.9.2

OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES

9.9.2.1

RECTAL TRANSMUCOSAL DRUG DELIVERY

9.9.2.1.1

ENHANCED BIOAVAILABILITY AND BYPASSING FIRST-PASS METABOLISM

9.9.2.2

VAGINAL TRANSMUCOSAL DRUG DELIVERY

9.9.2.2.1

HIGHER PERMEABILITY AND DIRECT ACCESS TO TARGET SYSTEMS DRIVE ADOPTION

9.10

IMPLANTABLE DRUG DELIVERY

9.10.1

ACTIVE IMPLANTABLE DRUG DELIVERY

9.10.1.1

ACTIVE IMPLANTABLE DEVICES ARE USED FOR DIAGNOSTIC MONITORING, BODY FLUID TRANSPORTATION, AND IONIZING RADIATION

9.10.2

PASSIVE IMPLANTABLE DRUG DELIVERY

9.10.2.1

PASSIVE IMPLANTABLE DRUG DELIVERY SYSTEMS OFFER A MEANS TO ACHIEVE TARGETED DRUG DELIVERY

9.11

OTIC DRUG DELIVERY

9.11.1

EAR DROPS

9.11.1.1

INCREASING PREVALENCE OF EAR INFECTIONS AND DEMAND FOR LOCALIZED TREATMENT ARE DRIVING EAR DROPS SEGMENT GROWTH

9.11.2

OTIC SPRAYS

9.11.2.1

GROWING DEMAND FOR UNIFORM DRUG DISTRIBUTION AND IMPROVED PATIENT CONVENIENCE DRIVING ADOPTION

PHARMACEUTICAL DRUG DELIVERY, BY APPLICATION

Market Size & Growth Rate Forecast Analysis to 2031 in USD Billion | 54 Data Tables

373

10.1

INTRODUCTION

10.2

INJECTABLE DRUG DELIVERY

10.2.1

METABOLIC DISORDERS (DIABETES, OBESITY)

10.2.1.1

RISING BURDEN OF DIABETES AND OBESITY DRIVING STRONG ADOPTION OF INJECTABLE DRUG DELIVERY

10.2.2

CANCER

10.2.2.1

RISING PREVALENCE OF CANCER AND GROWING AVAILABILITY OF THERAPEUTICS TO DRIVE MARKET

10.2.3

IMMUNOLOGICAL & AUTOIMMUNE DISEASES

10.2.3.1

INCREASED FOCUS ON EARLY-STAGE DIAGNOSIS AND TREATMENT TO PROPEL SEGMENT GROWTH

10.2.4

INFECTIOUS DISEASES

10.2.4.1

INCREASING USE OF LIPOSOMES TO AID SEGMENT GROWTH

10.2.5

OTHER INJECTABLE DRUG DELIVERY APPLICATIONS

10.3

ORAL DRUG DELIVERY

10.3.1

CARDIOVASCULAR DISEASES

10.3.1.1

HIGH PREVALENCE OF CVDS AND WIDESPREAD USE OF ORAL THERAPIES DRIVE MARKET

10.3.2

METABOLIC DISORDERS (DIABETES, OBESITY)

10.3.2.1

GROWING PREFERENCE FOR SELF-INJECTION DEVICES OVER TRADITIONAL SYRINGES TO AUGMENT MARKET GROWTH

10.3.3

CNS DISORDERS

10.3.3.1

CHRONIC NATURE OF CNS DISORDERS AND LONG-TERM THERAPY NEEDS DRIVING ORAL DRUG DELIVERY ADOPTION

10.3.4

INFECTIOUS DISEASES

10.3.4.1

HIGH GLOBAL INFECTION BURDEN AND OUTPATIENT TREATMENT TRENDS DRIVING ORAL DRUG DELIVERY ADOPTION

10.3.5

ONCOLOGY (ORAL THERAPIES)

10.3.5.1

SHIFT TOWARD TARGETED THERAPIES AND AT-HOME TREATMENT DRIVING ORAL DRUG DELIVERY IN ONCOLOGY

10.3.6

OTHER ORAL DRUG DELIVERY APPLICATIONS

10.4

TOPICAL DRUG DELIVERY

10.4.1

DERMATOLOGICAL DISORDERS

10.4.1.1

HIGH PREVALENCE OF SKIN DISORDERS DRIVING STRONG DEMAND FOR TOPICAL DRUG DELIVERY

10.4.2

PAIN MANAGEMENT

10.4.2.1

LOCALIZED RELIEF AND REDUCED SYSTEMIC SIDE-EFFECTS DRIVING TOPICAL DRUG DELIVERY IN PAIN MANAGEMENT

10.4.3

WOUND CARE

10.4.3.1

RISING INCIDENCE OF CHRONIC WOUNDS AND SURGICAL PROCEDURES DRIVING TOPICAL DRUG DELIVERY IN WOUND CARE

10.5

OCULAR DRUG DELIVERY

10.5.1

RETINAL DISORDERS

10.5.1.1

RISING PREVALENCE OF RETINAL DISEASES AND BIOLOGICS ADOPTION DRIVING GROWTH IN THE RETINAL DISORDERS SEGMENT

10.5.2

GLAUCOMA

10.5.2.1

HIGH PREVALENCE AND LIFELONG THERAPY REQUIREMENTS DRIVING OCULAR DRUG DELIVERY IN GLAUCOMA

10.5.3

EYE INFECTIOUS DISEASES

10.5.3.1

HIGH INCIDENCE OF OCULAR INFECTIONS AND NEED FOR RAPID LOCALIZED THERAPY DRIVING EYE INFECTIOUS DISEASES SEGMENT

10.5.4

OTHER OCULAR DRUG DELIVERY APPLICATIONS

10.6

PULMONARY DRUG DELIVERY

10.6.1

ASTHMA

10.6.1.1

HIGH GLOBAL ASTHMA PREVALENCE AND LIFELONG INHALATION THERAPY DRIVING PULMONARY DRUG DELIVERY DEMAND

10.6.2

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

10.6.2.1

CHRONIC DISEASE BURDEN AND HIGH RELIANCE ON INHALATION THERAPIES DRIVING PULMONARY DRUG DELIVERY IN COPD

10.6.3

PULMONARY INFECTIONS

10.6.3.1

HIGH BURDEN OF RESPIRATORY INFECTIONS AND NEED FOR RAPID DRUG ACTION DRIVING PULMONARY DRUG DELIVERY IN PULMONARY INFECTIONS

10.6.4

OTHER PULMONARY DRUG DELIVERY APPLICATIONS

10.7

NASAL DRUG DELIVERY

10.7.1

ALLERGIC RHINITIS

10.7.1.1

HIGH PREVALENCE OF ALLERGIC CONDITIONS DRIVING NASAL DRUG DELIVERY IN ALLERGIC RHINITIS

10.7.2

SINUSITIS

10.7.2.1

HIGH PREVALENCE OF SINUS INFECTIONS AND NEED FOR TARGETED THERAPY DRIVING NASAL DRUG DELIVERY IN SINUSITIS

10.7.3

OTHER NASAL DRUG DELIVERY APPLICATIONS

10.8

TRANSMUCOSAL DRUG DELIVERY

10.8.1

PAIN MANAGEMENT

10.8.1.1

RAPID ONSET AND IMPROVED PATIENT COMPLIANCE DRIVING TRANSMUCOSAL DRUG DELIVERY IN PAIN MANAGEMENT

10.8.2

HORMONE THERAPY

10.8.2.1

NEED FOR CONTROLLED HORMONE DELIVERY AND LONG-TERM THERAPY DRIVING TRANSMUCOSAL DRUG DELIVERY IN HORMONAL THERAPY

10.8.3

INFECTIOUS DISEASES

10.8.3.1

TARGETED LOCAL THERAPY AND IMPROVED PATIENT COMPLIANCE DRIVING TRANSMUCOSAL DRUG DELIVERY IN INFECTIOUS DISEASES

10.8.4

OTHER TRANSMUCOSAL DRUG DELIVERY APPLICATIONS

10.9

IMPLANTABLE DRUG DELIVERY

10.9.1

HORMONAL THERAPY/CONTRACEPTION

10.9.1.1

LONG-ACTING REVERSIBLE CONTRACEPTIVES AND SUSTAINED HORMONE DELIVERY DRIVING MARKET

10.9.2

CANCER

10.9.2.1

TARGETED THERAPY AND SUSTAINED DRUG RELEASE DRIVING IMPLANTABLE DRUG DELIVERY IN CANCER

10.9.3

OTHER IMPLANTABLE DRUG DELIVERY APPLICATIONS

10.10

OTIC DRUG DELIVERY

10.10.1

EAR INFECTIONS

10.10.1.1

HIGH INCIDENCE OF OTITIS AND PEDIATRIC BURDEN DRIVING OTIC DRUG DELIVERY IN EAR INFECTIONS

10.10.2

CERUMEN REMOVAL

10.10.2.1

GROWING DEMAND FOR EAR HYGIENE AND NON-INVASIVE TREATMENTS DRIVING OTIC DRUG DELIVERY IN CERUMEN REMOVAL

10.10.3

OTHER OTIC DRUG DELIVERY APPLICATIONS

PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 14 Data Tables

443

11.1

INTRODUCTION

11.2

FORMULATIONS, BY FACILITY OF USE

11.2.1

HOSPITALS

11.2.1.1

INCREASED HOSPITAL DEMAND FOR COMPLEX DRUG DELIVERY BOOSTS MARKET UPTAKE

11.2.2

HOME CARE SETTINGS

11.2.2.1

RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET

11.2.3

AMBULATORY SURGERY CENTERS/CLINICS

11.2.3.1

SHIFT TOWARD COST-EFFECTIVE OUTPATIENT CARE DRIVING ADOPTION OF DRUG DELIVERY SYSTEMS

11.2.4

DIAGNOSTIC CENTERS

11.2.4.1

RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH

11.2.5

LONG-TERM CARE SETTINGS

11.2.5.1

GROWING ELDERLY POPULATION AND CHRONIC DISEASE BURDEN TO DRIVE MARKET

11.2.6

OTHER FACILITIES OF USE

11.3

DEVICES, BY FACILITY OF USE

11.3.1

PHARMACEUTICAL COMPANIES

11.3.1.1

INCREASING FOCUS ON ADVANCED DRUG DELIVERY SYSTEMS DRIVING MARKET GROWTH

11.3.2

BIOTECHNOLOGY COMPANIES

11.3.2.1

ENABLING COMPLEX BIOLOGICS DELIVERY AND DECENTRALIZED CARE

11.3.3

CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)

11.3.3.1

FUELING INNOVATION THROUGH COST-EFFECTIVE AND SCALABLE MANUFACTURING SOLUTIONS

PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION

Comprehensive coverage of 9 Regions with country-level deep-dive of 23 Countries | 1519 Data Tables.

464

12.1

INTRODUCTION

12.2

NORTH AMERICA

12.2.1

NORTH AMERICA: MACROECONOMIC OUTLOOK

12.2.2

NORTH AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031

12.2.3

12.2.3.1

US TO DOMINATE NORTH AMERICAN PHARMACEUTICAL DRUG DELIVERY MARKET

12.2.4

CANADA

12.2.4.1

GOVERNMENT SUPPORT FOR RESEARCH AND THE PREVALENCE OF CHRONIC DISEASES TO DRIVE THE MARKET IN CANADA

12.3

EUROPE

12.3.1

EUROPE: MACROECONOMIC OUTLOOK

12.3.2

EUROPE: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031

12.3.3

GERMANY

12.3.3.1

GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON THE DEVELOPMENT OF VARIOUS DRUG DELIVERY PRODUCTS TO DRIVE MARKET

12.3.4

12.3.4.1

NHS SUPPORT AND GROWING ACCESS TO COST-EFFECTIVE PEN NEEDLES TO DRIVE THE MARKET

12.3.5

FRANCE

12.3.5.1

PRESENCE OF LEADING PHARMACEUTICAL COMPANIES, ALONG WITH THE INCREASING PREVALENCE OF CHRONIC DISEASES, TO DRIVE MARKET GROWTH IN FRANCE

12.3.6

ITALY

12.3.6.1

INCREASING FOCUS ON CLINICAL RESEARCH AND GROWING POPULARITY OF BRANDED DRUGS TO DRIVE DEMAND FOR PHARMACEUTICAL DRUG MANUFACTURING

12.3.7

DENMARK

12.3.7.1

STRONG R&D ECOSYSTEM, BIOLOGICS INNOVATION, AND EXPORT-DRIVEN PHARMACEUTICAL MANUFACTURING TO DRIVE DEMAND FOR PHARMACEUTICAL DRUG DELIVERY

12.3.8

SWEDEN

12.3.8.1

STRONG LIFE SCIENCES ECOSYSTEM, BIOLOGICS INNOVATION, AND GOVERNMENT-BACKED HEALTHCARE SYSTEM TO DRIVE DEMAND FOR PHARMACEUTICAL DRUG DELIVERY

12.3.9

SPAIN

12.3.9.1

INCREASE IN BIOLOGICS PRODUCTION TO SUPPORT MARKET GROWTH

12.3.10

NETHERLANDS

12.3.10.1

ENHANCING PATIENT CARE THROUGH INNOVATION AND COLLABORATION TO DRIVE MARKET GROWTH

12.3.11

REST OF EUROPE

12.4

ASIA PACIFIC

12.4.1

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2

ASIA PACIFIC: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031

12.4.3

CHINA

12.4.3.1

A HIGH DIABETIC POPULATION AND RISING PREVALENCE OF CHRONIC DISEASES CONTRIBUTE TO CHINA’S LARGE DEMAND

12.4.4

JAPAN

12.4.4.1

FAVORABLE GOVERNMENT INITIATIVES AND INCREASED GERIATRIC POPULATION TO DRIVE MARKET GROWTH IN JAPAN

12.4.5

INDIA

12.4.5.1

GROWING GENERIC DEMAND AND RISING GOVERNMENT INITIATIVES TO DRIVE MARKET

12.4.6

AUSTRALIA

12.4.6.1

RISING INVESTMENT AND A FAVORABLE TAX ENVIRONMENT TO SUPPORT GROWTH

12.4.7

SOUTH KOREA

12.4.7.1

STRONG GOVERNMENT SUPPORT AND INVESTMENTS IN HEALTHCARE & BIOPHARMACEUTICALS TO PROPEL GROWTH

12.4.8

NEW ZEALAND

12.4.8.1

STRONG PUBLIC HEALTHCARE SYSTEM, RISING BIOLOGICS ADOPTION, AND FOCUS ON ADVANCED THERAPIES TO DRIVE DEMAND

12.4.9

THAILAND

12.4.9.1

REGULATORY REFORMS AND HEALTHCARE INITIATIVES TO FUEL MARKET GROWTH

12.4.10

REST OF ASIA PACIFIC

12.5

LATIN AMERICA

12.5.1

FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM

12.5.2

LATIN AMERICA: MACROECONOMIC OUTLOOK

12.5.3

LATIN AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031

12.5.4

BRAZIL

12.5.4.1

BRAZIL ATTRACTING MULTINATIONAL PHARMACEUTICAL COMPANIES

12.5.5

MEXICO

12.5.5.1

GROWTH AND DIVERSIFICATION IN MEXICO'S PHARMACEUTICAL EXPORTS

12.5.6

ARGENTINA

12.5.6.1

EXPANDING DOMESTIC PHARMACEUTICAL PRODUCTION, INCREASING CHRONIC DISEASE BURDEN, AND GROWING BIOLOGICS ADOPTION TO DRIVE DEMAND

12.5.7

REST OF LATIN AMERICA

12.6

MIDDLE EAST & AFRICA

12.6.1

MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK

12.6.2

MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031

12.6.3

GCC COUNTRIES

12.6.3.1

KINGDOM OF SAUDI ARABIA (KSA)

12.6.3.1.1

HEALTHCARE REFORMS AND GLOBAL PARTNERSHIPS FUEL PHARMACEUTICAL MARKET GROWTH

12.6.3.2

UNITED ARAB EMIRATES (UAE)

12.6.3.2.1

GOVERNMENT SUPPORTS AND GROWING LOCAL MANUFACTURING TO DRIVE MARKET GROWTH

12.6.3.3

REST OF GCC COUNTRIES

12.6.4

REST OF MIDDLE EAST & AFRICA

COMPETITIVE LANDSCAPE

Discover key strategies and market dominance shaping the future of drug delivery manufacturers.

1008

13.1

OVERVIEW

13.2

KEY PLAYER STRATEGIES/RIGHT TO WIN

13.3

REVENUE ANALYSIS, 2023–2025

13.3.1

PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS

13.3.2

PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS

13.4

MARKET SHARE ANALYSIS, 2025

13.4.1

GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS

13.4.1.1

GLOBAL INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

13.4.1.2

GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

13.4.1.2.1

US INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

13.4.1.3

EUROPE INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

13.4.2

GLOBAL ORAL DRUG DELIVERY MANUFACTURERS

13.4.2.1

US ORAL DRUG DELIVERY FORMULATION MANUFACTURERS

13.4.2.2

EUROPE ORAL DRUG DELIVERY MANUFACTURERS

13.4.3

GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS

13.4.3.1

US TOPICAL DRUG DELIVERY FORMULATION MANUFACTURERS

13.4.3.2

EUROPE TOPICAL DRUG DELIVERY MANUFACTURERS

13.5

BRAND/PRODUCT COMPARISON

13.6

R&D EXPENDITURE OF KEY PLAYERS

13.7

COMPANY VALUATION AND FINANCIAL METRICS

13.7.1

COMPANY VALUATION

13.7.2

FINANCIAL METRICS

13.8

COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025

13.8.1

STARS

13.8.2

EMERGING LEADERS

13.8.3

PERVASIVE PLAYERS

13.8.4

PARTICIPANTS

13.8.5

COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025

13.8.5.1

COMPANY FOOTPRINT

13.8.5.2

REGION FOOTPRINT

13.8.5.3

PRODUCT TYPE FOOTPRINT

13.8.5.4

USABILITY FOOTPRINT

13.9

COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025

13.9.1

STARS

13.9.2

EMERGING LEADERS

13.9.3

PERVASIVE PLAYERS

13.9.4

PARTICIPANTS

13.9.5

COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025

13.9.5.1

COMPANY FOOTPRINT

13.9.5.2

REGION FOOTPRINT

13.9.5.3

ROUTE OF ADMINISTRATION FOOTPRINT

13.9.5.4

THERAPEUTIC APPLICATION FOOTPRINT

13.10

COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025

13.10.1

PROGRESSIVE COMPANIES

13.10.2

DYNAMIC COMPANIES

13.10.3

STARTING BLOCKS

13.10.4

RESPONSIVE COMPANIES

13.10.5

COMPETITIVE BENCHMARKING: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025

13.10.5.1

DETAILED LIST OF KEY STARTUPS/SMES

13.10.5.2

COMPETITIVE BENCHMARKING OF STARTUPS/SMES

13.11

COMPETITIVE SCENARIO

13.11.1

PRODUCT APPROVALS AND LAUNCHES

13.11.2

DEALS

13.11.3

EXPANSIONS

13.11.4

OTHER DEVELOPMENTS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

1044

14.1

PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS

14.1.1

JOHNSON & JOHNSON

14.1.1.1

BUSINESS OVERVIEW

14.1.1.2

PRODUCTS OFFERED

14.1.1.3

RECENT DEVELOPMENTS

14.1.1.3.1

PRODUCT APPROVALS

14.1.1.3.2

DEALS

14.1.1.3.3

EXPANSIONS

14.1.1.3.4

OTHER DEVELOPMENTS

14.1.1.4

MNM VIEW

14.1.1.4.1

RIGHT TO WIN

14.1.1.4.2

STRATEGIC CHOICES

14.1.1.4.3

WEAKNESSES AND COMPETITIVE THREATS

14.1.2

NOVARTIS AG

14.1.3

F. HOFFMANN-LA ROCHE LTD

14.1.4

PFIZER INC.

14.1.5

ELI LILLY AND COMPANY

14.1.6

GSK PLC.

14.1.7

ABBVIE INC.

14.1.8

MERCK & CO., INC.

14.1.9

BAUSCH HEALTH COMPANIES INC.

14.1.10

BAYER AG

14.1.11

AMGEN INC.

14.1.12

ASTRAZENECA

14.1.13

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.2

OTHER PLAYERS

14.2.1

SANOFI

14.2.2

NOVO NORDISK A/S

14.2.3

GLENMARK PHARMACEUTICALS LTD.

14.2.4

VIATRIS INC

14.2.5

BRISTOL-MYERS SQUIBB COMPANY

14.2.6

RUSAN PHARMA LTD.

14.2.7

CMP PHARMA, INC.

14.2.8

XERIS PHARMACEUTICALS, INC.

14.2.9

ADHEXPHARMA

14.3

PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS

14.3.1

14.3.2

CARDINAL HEALTH

14.3.3

B. BRAUN SE

14.3.4

TERUMO CORPORATION

14.3.5

NIPRO

14.3.6

STEVANATO GROUP

14.3.7

GERRESHEIMER AG

14.3.8

WEST PHARMACEUTICAL SERVICES, INC.

14.3.9

YPSOMED

14.3.10

SHL MEDICAL AG

RESEARCH METHODOLOGY

1246

15.1

RESEARCH DATA

15.1.1

SECONDARY DATA

15.1.1.1

KEY SECONDARY SOURCES

15.1.2

PRIMARY DATA

15.1.2.1

PRIMARY SOURCES

15.1.2.2

KEY DATA FROM PRIMARY SOURCES

15.1.2.3

KEY INDUSTRY INSIGHTS

15.1.2.4

BREAKDOWN OF PRIMARIES

15.2

MARKET SIZE ESTIMATION

15.2.1

APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH

15.2.2

APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION

15.2.3

APPROACH 3: TOP-DOWN APPROACH

15.2.4

APPROACH 4: BOTTOM-UP APPROACH

15.2.5

APPROACH 4: PRIMARY INTERVIEWS

15.2.6

APPROACH 5: DEMAND-SIDE APPROACH

15.2.7

APPROACH 6: VOLUME DATA ANALYSIS

15.3

DATA TRIANGULATION AND MARKET BREAKDOWN

15.4

MARKET SHARE ASSESSMENT

15.5

RESEARCH ASSUMPTIONS

15.5.1

STUDY ASSUMPTIONS

15.5.2

GROWTH RATE ASSUMPTIONS

15.6

RISK ASSESSMENT

15.6.1

RESEARCH LIMITATIONS

APPENDIX

1264

16.1

DISCUSSION GUIDE

16.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

16.3

CUSTOMIZATION OPTIONS

16.3.1

PRODUCT ANALYSIS

16.3.2

Methodology

This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

Secondary Research

This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the veterinary imaging market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

Primary Research

In the primary research process, a range of sources from the supply and demand sides were used to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the pharmaceutical drug delivery market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes, and contract research organizations.

A breakdown of the primary respondents is provided below:

Pharmaceutical Drug Delivery Market
Size, and Share

Note: C-level executives include CEOs, COOs, CTOs, and VPs. Other designations include sales, marketing, and product managers.

Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the pharmaceutical drug delivery market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Pharmaceutical Drug Delivery Market : Top-Down and Bottom-Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Pharmaceutical drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.

Key Stakeholders

Pharmaceutical manufacturing companies
Original equipment manufacturing companies
Suppliers and distributors of pharmaceutical products and medical devices
Healthcare service providers
Teaching hospitals and academic medical centers
Health insurance players
Government bodies/municipal corporations
Regulatory bodies
Medical research institutes
Business research and consulting service providers
Venture capitalists
Market research and consulting firms

Report Objectives

To describe and forecast the global pharmaceutical drug delivery market, by route of administration, application, facility of use, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, Netherlands, Denmark, Sweden, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa [Turkey, GCC Countries (Saudi Arabia, the UAE and Rest of GCC) and Rest of Middle East & Africa]
To profile the key market players and comprehensively analyze their market shares and core competencies2
To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global pharmaceutical drug delivery market

Customization Options

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global pharmaceutical drug delivery market report.

Product Analysis

Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Geographic Analysis

Further breakdown of the Rest of Europe pharmaceutical drug delivery market into Austria, Switzerland, Finland, Sweden, Poland, and Portugal, among other countries
Further breakdown of the Rest of Asia Pacific pharmaceutical drug delivery market into Vietnam, Philippines, Singapore, Malaysia, and Indonesia, among other countries
Further breakdown of the Rest of Latin America pharmaceutical drug delivery market into Chile and Colombia, among other countries.

Country-Level Volume Analysis By Product

Quantifies volumes by major service types for selected countries to show demand patterns. Product Type Market Share Analysis (Top 5 Players).

By Route Of Administration Market Share Analysis (Top 5 Players)

Route of Administration Market Share Analysis (Top 5 Players).

Any Consult/Custom Requirements As Per Client Requests

Provides tailored analyses, datasets, and deliverables based on specific client briefs..

Logan

Jun, 2026

I reviewed the Pharmaceutical Drug Delivery Market report to evaluate how shifting formulation technologies are reshaping our pipeline prioritization, especially for complex biologics and controlled-release systems..

Skye

While going through the Pharmaceutical Drug Delivery Market insights, I focused on the technical segmentation of oral, injectable, and transdermal systems to understand where device�drug integration is creating real development bottlenecks in manufacturing scalability..

Ryker

After analyzing the Pharmaceutical Drug Delivery Market outlook, I assessed the investment implications around sustained-release and targeted delivery platforms, particularly in terms of regulatory complexity and long-term commercialization feasibility..

Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031

PHARMACEUTICAL DRUG DELIVERY MARKET SIZE, SHARE & GROWTH SNAPSHOT

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Increasing shift toward self-administration and home-based care worldwide

Restraint: High development costs and stringent global regulatory requirements

Opportunity: Increasing adoption of long-acting and targeted delivery technologies

Challenge: Complex regulatory environments, supply chain, and sterility issues

PHARMACEUTICAL DRUG DELIVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

Pharmaceutical Drug Delivery Market, By Route of Administration

Pharmaceutical Drug Delivery Market, By Application

Pharmaceutical Drug Delivery Market, By Facility of Use

REGION

Asia Pacific to be fastest-growing region in global pharmaceutical drug delivery market during forecast period

PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: PHARMACEUTICAL DRUG DELIVERY MARKET REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Pharmaceutical Drug Delivery Market : Top-Down and Bottom-Up Approach

Data Triangulation

Market Definition

Key Stakeholders

Report Objectives

Customization Options

Product Analysis

Company Information

Geographic Analysis

Country-Level Volume Analysis By Product

By Route Of Administration Market Share Analysis (Top 5 Players)

Any Consult/Custom Requirements As Per Client Requests

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Adjacent Markets

Personalize This Research

Let Us Help You

TESTIMONIALS

JAYANT RAJPUROHIT

SFI Health,

BEATRIZ DE LA CALLE

Qualicaps,

Bob Williams,

Bracco Diagnostics Inc.,

Cody Coonradt,

3M Health Information Systems,

Growth opportunities and latent adjacency in Pharmaceutical Drug Delivery Market

Logan

Skye

Ryker

Gregory

Alexander

Frank